| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10048-011-0294-5 |
| P698 | PubMed publication ID | 21800131 |
| P2093 | author name string | Ronald K B Pearce | |
| Gregory J Michael | |||
| Manuel B Graeber | |||
| Linda B Moran | |||
| Sharmin Esmailzadeh | |||
| Lynne Christian | |||
| P2860 | cites work | Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis | Q21266563 |
| Expression of metallothionein-III induced by hypoxia attenuates hypoxia-induced cell death in vitro | Q24302373 | ||
| PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease | Q24597726 | ||
| Human-specific nonsense mutations identified by genome sequence comparisons | Q28290107 | ||
| Metallothionein in bovine spongiform encephalopathy | Q48442482 | ||
| Region-dependent differences and alterations of protective thiol compound levels in cultured astrocytes and brain tissues | Q48479816 | ||
| Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease. | Q48540299 | ||
| Glial fibrillary acidic protein-positive cells of the kidney are capable of raising a protective biochemical barrier similar to astrocytes: expression of metallothionein in podocytes | Q48543815 | ||
| Glial immunoreactivity for metallothionein in the rat brain | Q48820458 | ||
| Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms | Q48846656 | ||
| Astrocyte-targeted expression of interleukin-3 and interferon-alpha causes region-specific changes in metallothionein expression in the brain | Q48946647 | ||
| DnaJB6 is present in the core of Lewy bodies and is highly up-regulated in parkinsonian astrocytes. | Q48961761 | ||
| Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. | Q51923343 | ||
| Metallothionein-I-II and GFAP positivity in the brains from frontotemporal dementia patients. | Q53375639 | ||
| Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity. | Q53530590 | ||
| Metallothionein-1+2 Protect the CNS after a Focal Brain Injury | Q58027806 | ||
| The expression of metallothioneins is diminished in the spinal cords of patients with sporadic ALS | Q58247190 | ||
| The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease | Q64797268 | ||
| Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+ | Q68821467 | ||
| Involvement of oxidative stress in the synthesis of metallothionein induced by mitochondrial inhibitors | Q79174970 | ||
| Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease | Q79182812 | ||
| Metallothionein-3 is expressed in the brain and various peripheral organs of the rat | Q81276304 | ||
| Metallothionein-3 regulates lysosomal function in cultured astrocytes under both normal and oxidative conditions | Q28510613 | ||
| Metallothionein induces a regenerative reactive astrocyte phenotype via JAK/STAT and RhoA signalling pathways | Q28578482 | ||
| Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis | Q30811004 | ||
| Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression | Q34084772 | ||
| Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes | Q34332336 | ||
| Chemistry and biology of mammalian metallothioneins. | Q34629949 | ||
| Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury | Q35674443 | ||
| Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation | Q36453886 | ||
| Metallothioneins I and II: neuroprotective significance during CNS pathology | Q36650001 | ||
| Glial reactions in Parkinson's disease | Q37017536 | ||
| Metallothionein-I+II in neuroprotection | Q37572637 | ||
| Metallothionein protein evolution: a miniassay. | Q37883960 | ||
| Altered expression of metallothionein-I and -II and their receptor megalin in inherited photoreceptor degeneration | Q38345227 | ||
| Protective effects of metallothionein against dopamine quinone-induced dopaminergic neurotoxicity | Q40073295 | ||
| Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson's disease and the neuroprotective role of coenzyme Q10. | Q40272026 | ||
| Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons | Q40282798 | ||
| Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase | Q40330344 | ||
| Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins | Q40350659 | ||
| Astrocyte metallothioneins (MTs) and their neuroprotective role | Q40877767 | ||
| Differential regulation of metallothionein-I, II, and III mRNA expression in the rat brain following kainic acid treatment | Q42439678 | ||
| Metallothionein and brain injury after intracerebral hemorrhage. | Q42446164 | ||
| Ontogenesis and migration of metallothionein I/II-containing glial cells in the human telencephalon during the second trimester | Q43141489 | ||
| Metallothionein isoform 2A expression is inducible and protects against ROS-mediated cell death in rotenone-treated HeLa cells | Q43258175 | ||
| M-CSF deficiency leads to reduced metallothioneins I and II expression and increased tissue damage in the brain stem after 6-aminonicotinamide treatment | Q44163890 | ||
| Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. | Q44418999 | ||
| Zinc- or cadmium-pre-induced metallothionein protects human central nervous system cells and astrocytes from radiation-induced apoptosis | Q44700930 | ||
| Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid-induced epileptic seizures | Q45198348 | ||
| Astroglial nitration after postnatal excitotoxic damage: correlation with nitric oxide sources, cytoskeletal, apoptotic and antioxidant proteins | Q45234874 | ||
| Copper and zinc dismetabolism in the mouse brain upon chronic cuprizone treatment. | Q46560685 | ||
| Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases | Q46729233 | ||
| Glial dysfunction in parkin null mice: effects of aging. | Q46804912 | ||
| Neuron-glia communication: metallothionein expression is specifically up-regulated by astrocytes in response to neuronal injury | Q47303332 | ||
| Zn and Cu alteration in connection with astrocyte metallothionein I/II overexpression in the mouse brain upon physical stress | Q47616341 | ||
| Neuronal apoptosis, metallothionein expression and proinflammatory responses during cerebral malaria in mice | Q48027809 | ||
| Metallothionein-IIA promotes neurite growth via the megalin receptor. | Q48102795 | ||
| Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia. | Q48108493 | ||
| Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease | Q48132477 | ||
| Basic science; metallothionein I and II attenuate the thalamic microglial response following traumatic axotomy in the immature brain. | Q48293421 | ||
| Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression | Q48345931 | ||
| Metallothionein-I overexpression decreases brain pathology in transgenic mice with astrocyte-targeted expression of interleukin-6. | Q48363883 | ||
| Quantitative immunogold study of increased expression of metallothionein-I/II in the brain perivascular areas of diabetic scrapie-infected mice | Q48399936 | ||
| Metallothionein-I and -III expression in animal models of Alzheimer disease | Q48402258 | ||
| Expression of metallothionein-I, -II, and -III in Alzheimer disease and animal models of neuroinflammation | Q48405270 | ||
| Metallothioneins are highly expressed in astrocytes and microcapillaries in Alzheimer's disease | Q48408590 | ||
| Metallothionein I-II immunocytochemical reactivity in Binswanger's encephalopathy. | Q48412941 | ||
| Novel roles for metallothionein-I + II (MT-I + II) in defense responses, neurogenesis, and tissue restoration after traumatic brain injury: insights from global gene expression profiling in wild-type and MT-I + II knockout mice | Q48433929 | ||
| P433 | issue | 4 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| astrocyte | Q502961 | ||
| P304 | page(s) | 295-305 | |
| P577 | publication date | 2011-07-29 | |
| P1433 | published in | Neurogenetics | Q15710048 |
| P1476 | title | Up-regulation of metallothionein gene expression in parkinsonian astrocytes. | |
| P478 | volume | 12 |
| Q37655091 | A network view on Parkinson's disease |
| Q93122481 | A systems biology approach towards the identification of candidate therapeutic genes and potential biomarkers for Parkinson's disease |
| Q23924036 | An investigation of modifying effects of metallothionein single-nucleotide polymorphisms on the association between mercury exposure and biomarker levels |
| Q37616391 | Copper and copper proteins in Parkinson's disease |
| Q57492442 | Cu(atsm) Attenuates Neuroinflammation |
| Q34389461 | Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice. |
| Q93086774 | Innate immune responses to paraquat exposure in a Drosophila model of Parkinson's disease |
| Q35899904 | Integrative analyses of proteomics and RNA transcriptomics implicate mitochondrial processes, protein folding pathways and GWAS loci in Parkinson disease |
| Q42709080 | Metallothionein in Brain Disorders |
| Q37737068 | Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. |
| Q38723681 | Metallothioneins in Normal and Cancer Cells. |
| Q38887346 | Molecular changes in the postmortem parkinsonian brain |
| Q42460533 | Neuroprotective effects of metallothionein against rotenone-induced myenteric neurodegeneration in parkinsonian mice |
| Q57649750 | Neurotoxicity Linked to Dysfunctional Metal Ion Homeostasis and Xenobiotic Metal Exposure: Redox Signaling and Oxidative Stress |
| Q28079379 | Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease |
| Q64243678 | Switching on Endogenous Metal Binding Proteins in Parkinson's Disease |
| Q59544567 | The Role of Astrocytes in Parkinson’s Disease |
| Q35145894 | The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration |
| Q36326535 | Thiol-redox signaling, dopaminergic cell death, and Parkinson's disease |
Search more.